NHERF2

NHERF2 (SLC9A3R2/E3KARP) is a dual-PDZ domain scaffold protein that assembles signal-specific multiprotein complexes at the apical membrane of polarized epithelial cells and neurons, linking transmembrane ion transporters, channels, and G protein-coupled receptors to cytoskeletal anchors and kinase effectors. Its PDZ domains (especially PDZ2) bind the C-terminal motifs of NHE3, CFTR, LPA2, LPA5, P2Y1R, mGluR5, and other targets, while its C-terminal ERM-binding domain tethers these complexes to ezrin and the actin cytoskeleton, thereby positioning kinases (PKA, PKCα, cGKII, SGK1, CaMKIIγ) near their transporter substrates to mediate cAMP-, cGMP-, Ca²⁺-, LPA-, and glucocorticoid-dependent regulation of NHE3 activity, CFTR channel function, and ROMK1/TRPV5 membrane retention (PMID:9748260, PMID:15722341, PMID:21191106, PMID:20962002, PMID:19800338). Phosphorylation of Ser303 in the NHERF2 C-terminal regulatory sequence by A-Raf during mitosis reduces ezrin binding and dynamically releases NHERF2-tethered complexes from the cytoskeleton, providing a mechanism for regulated trafficking of apical transporters (PMID:26251448, PMID:26310448). NHERF2 also heterodimerizes with NHERF3 via PDZ-mediated interactions to form macromolecular complexes required for Ca²⁺- and cGMP-dependent NHE3 inhibition in intestinal epithelium, and functions outside the apical membrane as a coactivator of estrogen receptor α and a stabilizer of IκB that suppresses NF-κB signaling (PMID:24867958, PMID:24771346, PMID:37573425).

1. 1998 High

   The fundamental question of how cAMP-dependent kinase is positioned near NHE3 was answered by the discovery that NHERF2 directly bridges NHE3 to ezrin (a PKA type II anchoring protein) via its PDZ2 and C-terminal domains, establishing NHERF2 as a scaffolding adaptor rather than a kinase substrate.

   Evidence In vitro binding assays with domain mapping, co-IP, and co-localization in PS120 fibroblasts and opossum kidney cells

   PMID:9748260 PMID:9792717

   Open questions at the time

   • Structural basis of the PDZ2–NHE3 interaction not yet defined
   • In vivo relevance not yet tested with knockout models
2. 2000 High

   NHERF2's scaffolding role was extended beyond NHE3 when it was shown to bind CFTR with nanomolar affinity via PDZ2, co-localize with CFTR at the apical membrane, and potentiate cAMP-stimulated CFTR Cl⁻ currents when reconstituted with ezrin in oocytes.

   Evidence Co-IP, confocal microscopy, cell fractionation, and Xenopus oocyte electrophysiology

   PMID:10893422

   Open questions at the time

   • Whether NHERF2 simultaneously scaffolds NHE3 and CFTR not tested
   • In vivo significance of CFTR regulation by NHERF2 not yet established
3. 2001 High

   Signal specificity of NHERF2 scaffolding was demonstrated when glucocorticoid-induced NHE3 activation was found to require NHERF2 (not NHERF1) and SGK1, establishing that different second-messenger pathways are routed through specific scaffold–kinase combinations.

   Evidence NHE3 activity assays in PS120 and opossum kidney cells with dominant-negative SGK1

   PMID:11751930

   Open questions at the time

   • Whether SGK1 directly binds PDZ domains or an adjacent region not precisely mapped
   • Other kinases that use NHERF2 as anchor not yet identified
4. 2002 High

   The mechanism of Ca²⁺-dependent NHE3 inhibition was resolved: elevated Ca²⁺ induces α-actinin-4 binding to NHERF2, forming an NHE3–NHERF2–α-actinin-4 complex that drives NHE3 oligomerization and endocytosis, a process requiring NHERF2 but not NHERF1.

   Evidence NHE3 activity assays in PS120 cells, co-IP, dominant-negative overexpression, endocytosis assays

   PMID:11948184

   Open questions at the time

   • How α-actinin-4 binding triggers oligomerization is unknown
   • Role of PKCα in the Ca²⁺ pathway not yet integrated
5. 2003 High

   PKCα was identified as the effector kinase downstream of Ca²⁺ signaling that binds NHERF2 PDZ1 to drive NHE3 endocytosis, separating the oligomerization and endocytosis steps of Ca²⁺-dependent NHE3 inhibition.

   Evidence PKC inhibitors, GST pulldown, co-IP, surface biotinylation in PS120 cells

   PMID:12954600

   Open questions at the time

   • Direct PKCα phosphorylation site on NHE3 in this context not identified
   • Whether PKCα and α-actinin-4 bind NHERF2 simultaneously not tested
6. 2004 High

   NHERF2's scaffolding was extended to GPCR signaling when LPA2 receptor was shown to bind NHERF2 PDZ2, forming a ternary complex with PLC-β3 that potentiates LPA-induced ERK/COX-2 signaling, and LPA was shown to drive NHERF2-dependent exocytic trafficking of NHE3.

   Evidence Co-IP, siRNA knockdown, mutagenesis, PLC activity assays, NHE3 surface quantification with pharmacological inhibitors

   PMID:15143197 PMID:15238220

   Open questions at the time

   • Whether the LPA2–NHERF2–PLC-β3 complex exists at the apical membrane in polarized epithelia not confirmed
   • Which kinase downstream of PLC executes NHE3 exocytosis not yet defined
7. 2005 High

   NHERF2 was established as a cGKII-anchoring protein required for cGMP-dependent NHE3 inhibition, and simultaneously shown to scaffold P2Y1R and mGluR5 to PLC-β, prolonging receptor-mediated Ca²⁺ signaling in neurons and glia.

   Evidence NHE3 activity assays with myristoylation mutants; PDZ array, co-IP, Ca²⁺ signaling assays with point mutations in glial cells and sympathetic neurons

   PMID:15722341 PMID:15901899 PMID:16891310

   Open questions at the time

   • Whether cGKII and P2Y1R/mGluR5 compete for PDZ2 occupancy not tested
   • NHERF2 role in neuronal signaling in vivo not confirmed
8. 2009 High

   In vivo validation came from Nherf2-knockout mice, which showed augmented CFTR-dependent HCO₃⁻ secretion, loss of LPA-mediated inhibition of HCO₃⁻ secretion, and impaired LPA-stimulated fluid absorption via NHE3/LPA5, confirming NHERF2 as a physiologically essential scaffold for intestinal ion transport.

   Evidence Nherf2⁻/⁻ mouse duodenal secretion and intestinal absorption assays, laser microdissection/qPCR

   PMID:19221439 PMID:19800338

   Open questions at the time

   • Compensatory roles of NHERF1 or NHERF3 in knockout intestine not fully dissected
   • Kidney phenotype of Nherf2-null mice not characterized
9. 2010 High

   FRET and FRAP studies revealed the dynamic nature of the NHERF2–NHE3 complex: LPA stimulation causes PI3K-dependent exocytic trafficking and PI3K-independent dissociation of NHE3 from NHERF2, while Nherf2-null intestine confirmed NHERF2 tethers NHE3 near the terminal web and is required for Ca²⁺- and cGMP-dependent NHE3 inhibition.

   Evidence FRAP, acceptor photobleaching FRET, co-precipitation kinetics in OK cells; Nherf2⁻/⁻ mouse immunolocalization and NHE3 activity

   PMID:20571054 PMID:20962002

   Open questions at the time

   • Identity of the kinase that phosphorylates NHE3 upon LPA to trigger dissociation from NHERF2 not defined
   • How NHE3–NHERF2 reassociation occurs mechanistically is unknown
10. 2010 High

    NHERF2 was shown to determine GPCR coupling specificity in neurons, selectively reducing CaV2.2 inhibition by P2Y1R and mGluR5 while leaving α2-adrenoceptor signaling unaffected, and to direct LPA2 preferentially toward Gαq coupling and pro-migratory signaling in colon cancer cells.

    Evidence Patch-clamp electrophysiology with binding-motif mutants in sympathetic neurons; co-IP, knockdown/overexpression with migration assays in colon cancer cells

    PMID:20720114 PMID:21134377

    Open questions at the time

    • Structural basis for NHERF2 selection of Gαq over Gα12 coupling unknown
    • In vivo neuronal phenotype of Nherf2 loss not tested
11. 2012 High

    CaMKIIγ was identified as a constitutive NHE3-binding kinase whose basal inhibition of NHE3 turnover number requires NHERF2, adding a fourth kinase pathway (beyond PKA, SGK1, cGKII) scaffolded by NHERF2 at NHE3.

    Evidence CaMKII inhibitors, back phosphorylation, co-IP, NHE3 C-terminal deletion mutants

    PMID:22371496

    Open questions at the time

    • CaMKIIγ direct phosphorylation site on NHE3 not identified
    • How Ca²⁺ elevation paradoxically reduces CaMKII–NHE3 association is mechanistically unclear
12. 2014 High

    NHERF2–NHERF3 heterodimerization was found to be the strongest inter-NHERF interaction, forming macromolecular complexes where both PDZ domains of NHERF2 are simultaneously occupied; this heterodimerization is functionally required for carbachol-mediated NHE3 inhibition.

    Evidence Pulldown, co-IP, FRET, FRAP, and mutagenesis in Caco-2 cells

    PMID:24867958

    Open questions at the time

    • Stoichiometry of the NHERF2–NHERF3–NHE3 macrocomplex not defined
    • Whether NHERF2–NHERF3 heterodimer has additional client proteins beyond NHE3 unknown
13. 2015 High

    A key regulatory switch was identified: phosphorylation of Ser303 in the NHERF2 C-terminal ERM-binding regulatory sequence by A-Raf during mitosis reduces ezrin binding, displaces NHERF2 from microvilli to the cytosol, and prevents dexamethasone-stimulated NHE3 activation, establishing a mechanism for dynamic release of the scaffold.

    Evidence FRAP, co-IP, phosphomimetic/phosphodeficient mutants, A-Raf identification, NHE3 activity assays

    PMID:26251448 PMID:26310448

    Open questions at the time

    • Other kinases that phosphorylate Ser303 outside mitosis not identified
    • Whether Ser303 phosphorylation also regulates CFTR or GPCR complexes not tested
14. 2023 Medium

    NHERF2 was found to function beyond ion transport as a stabilizer of IκB by reducing its ubiquitination, thereby inhibiting NF-κB signaling in colorectal cancer cells, with SLC26A3 augmenting this interaction.

    Evidence Co-IP, ubiquitination assays, siRNA knockdown, NF-κB reporter assays

    PMID:37573425

    Open questions at the time

    • Whether NHERF2 binds IκB directly via PDZ domains or indirectly is unclear
    • In vivo relevance to intestinal inflammation not tested in knockout mice
15. 2024 Medium

    NHERF2 was shown to organize NHE3 and cGKII into lipid raft-associated apical microdomains, and linaclotide-induced cGKII-dependent removal of NHE3 from rafts is strongly reduced in NHERF2-null mice, placing NHERF2 as a determinant of microdomain organization for cGMP signaling.

    Evidence Optiprep density gradient fractionation of brush border membranes from wild-type and Nherf2⁻/⁻ mice, confocal microscopy, in vivo linaclotide treatment

    PMID:38533975

    Open questions at the time

    • Whether NHERF2 directly targets NHE3 to lipid rafts or indirectly via ezrin is unresolved
    • Role of NHERF2 in raft organization for other client proteins not examined

• Full-length structural information for NHERF2 (beyond the PDZ1 crystal structure) and the atomic basis for its preferential binding hierarchy among dozens of client proteins remain unresolved; the physiological consequences of NHERF2 loss in kidney, brain, and reproductive tissues are largely untested in vivo.
• No full-length NHERF2 structure available
• Kidney and neuronal phenotypes of Nherf2-null mice not systematically characterized
• How NHERF2 selects among competing PDZ ligands in vivo is unknown